2025 Cystic Fibrosis Market Size, Company Share And Distribution Share Data And Analysis
"The
Latest Research Report OpportunityAnalyzer: Cystic Fibrosis -
Opportunity Analysis and Forecasts to 2025 provides information on
pricing, market analysis, shares, forecast, and company profiles for
key industry participants. - MarketResearchReports.biz"
About
Cystic Fibrosis Market
Cystic fibrosis (CF) is an
autosomal recessive disease caused by mutations in the cystic
fibrosis transmembrane conductance regulator (CFTR) gene, which codes
for the CFTR protein. As a multisystem condition, CF patients show
great heterogeneity in presenting clinical symptoms. CF mainly
affects the respiratory and gastrointestinal tracts. Three classes of
drugs have been used to for treatment in CF patients: inhaled
antibiotics for bacterial and fungal respiratory infections,
mucolytic drugs for mucociliary clearance of the airways, and
pancreatic enzyme replacement therapies (PERTs) for treatment of CF
induced exocrine pancreatic insufficiency (EPI). During the last five
years, a new class of drugs was launched into the market,
specifically treating the underlying cause of CF. These CFTR
modulators help restore function of the insufficient CFTR protein.
GlobalData projects the global cystic fibrosis marketplace to
experience tremendous growth during the forecast period. This growth
will be driven primarily by the highly anticipated arrival of the
CFTR modulator, Vertex Pharmaceuticals' ivacaftor/tezacaftor.
Insmed's inhaled antibiotic Arikace (liposomal amikacin) is also
expected to launch during the forecast period but is not expected to
drive CF market growth as much as the CFTR modulator, since it will
be competing with other inhaled antibiotics.
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/1177518
Key Questions Answered
- Inhaled antibiotics, mucolytic
drugs, and PERTs have been the cornerstone of CF treatment. The
introduction of CFTR modulators have contributed to better treatment
of CF patients; nevertheless, the overall life expectancy in CF
patients is still 20-25 years less than in the healthy population.
Therefore, there are considerably high unmet needs within the
indication. What are the main unmet needs in this market? Will the
drugs under development fulfil the unmet needs of the CF market?
- The current late-stage CF
pipeline encompasses one CFTR modulating combination therapy and an
inhaled antibiotic. Will the late-stage drugs make a significant
impact on the CF market? Which of these drugs will have the highest
peak sales at the highest CAGR, and why?
- CFTR modulators treat the cause
of the CF disease. How will the entrance of CFTR modulators into the
CF therapy market affect the other classes of drugs?
Scope
- Overview of cystic fibrosis,
including epidemiology, etiology, pathophysiology, symptoms,
diagnosis, and treatment guidelines.
- Annualized CF therapeutics
market revenue, annual cost of therapy and treatment usage pattern
data from 2015 and forecast for ten years to 2025.
- Key topics covered include
strategic competitor assessment, market characterization, unmet
needs, clinical trial mapping and implications for the CF
therapeutics market.
- Pipeline analysis: comprehensive
data split across different phases, emerging novel trends under
development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and
future market competition in the global CF therapeutics market.
Insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline. Additionally a list of acquisition
targets included in the pipeline product company list.
- Develop business strategies by
understanding the trends shaping and driving the global CF
therapeutics market.
- Drive revenues by understanding
the key trends, innovative products and technologies, market
segments, and companies likely to impact the global CF therapeutics
market in future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analysing the performance of various competitors.
- Identify emerging players with
potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Track drug sales in the global
CF therapeutics market from 2015-2025.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments
and strategic partnerships.
Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 7
2 Cystic Fibrosis: Executive
Summary 9
2.1 CF Transmembrane Conductance
Regulator Modulators Expected to Drive Substantial Growth in the
Cystic Fibrosis Market from 2015-2025 9
2.2 Licensing Activity and the
Formation of New Partnerships Will Steer Small Companies to Continue
Research of Novel Compounds 11
2.3 Marketed and Pipeline CF
Transmembrane Conductance Regulator Modulators Will Provide
Appropriate Treatment for the Majority of the CF Population, but the
High Unmet Needs Will Remain 12
2.4 Opportunities Will Remain for
the Development of New CF Transmembrane Conductance Regulator
Modulators 12
2.5 What Do Physicians Think? 13
Send An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/1177518
3 Introduction 15
3.1 Catalyst 15
3.2 Related Reports 15
3.3 Upcoming Related Reports 15
4 Disease Overview 16
4.1 Etiology and Pathophysiology
16
4.1.1 Etiology 16
4.1.2 Pathophysiology 16
4.2 Classification 20
4.3 Symptoms 21
4.4 Prognosis 22
4.5 Quality of Life 23
5 Epidemiology 24
5.1 Disease Background 24
5.2 Risk Factors and Comorbidities
25
5.3 Global Trends 26
5.3.1 Diagnosed Incidence and
Diagnosed Prevalence 27
5.4 Forecast Methodology 29
5.4.1 Sources Used 29
5.4.2 Forecast Assumptions and
Methods 37
5.4.3 Sources Not Used 49
5.5 Epidemiological Forecast for
CF (2015-2025) 50
5.5.1 Diagnosed Incident Cases,
Based on Registry Data 50
5.5.2 Diagnosed Prevalent Cases,
Based on Registry Data 53
5.5.3 CF Mortality, Based on
Registry Data 62
5.5.4 Diagnosed Incident Cases,
Adjusted for Underestimation 65
5.5.5 Diagnosed Prevalent Cases,
Adjusted for Underestimation 68
5.5.6 CF Mortality, Adjusted for
Underestimation 76
5.6 Discussion 79
5.6.1 Epidemiological Forecast
Insight 79
5.6.2 Limitations of the Analysis
80
5.6.3 Strengths of the Analysis 81
6 Current Treatment Options 82
6.1 Overview 82
6.2 Diagnosis and Treatment 83
6.2.1 Diagnosis 83
6.2.2 Treatment Guidelines and
Leading Prescribed Drugs 84
6.3 Clinical Practice 85
6.4 Product Profiles - Major
Brands, Inhaled Antibiotics 86
6.4.1 TOBI (tobramycin) 86
6.4.2 TOBI Podhaler (tobramycin)
89
6.4.3 Quinsair (levofloxacin) 93
6.4.4 Cayston (aztreonam) 95
6.4.5 Bramitob/Bethkis
(tobramycin) 99
6.4.6 Colobreathe (colistimethate
sodium) 102
6.5 Product Profiles - Major
Brands, Mucolytics 105
6.5.1 Pulmozyme (dornase alfa) 105
6.5.2 Bronchitol (mannitol) 109
6.6 Product Profiles - Major
Brands, CF Transmembrane Conductance Regulator Modulators 113
6.6.1 Kalydeco (ivacaftor) 113
6.6.2 Orkambi (ivacaftor +
lumacaftor) 118
6.7 Product Profiles - Major
Brands, Other Therapies 121
6.7.1 Pancreatic Enzyme
Replacement Therapies 121
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
Comments
Post a Comment